Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years
Summary Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from...
Gespeichert in:
| Veröffentlicht in: | Journal of voice 2017-05, Vol.31 (3), p.363-365 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 365 |
|---|---|
| container_issue | 3 |
| container_start_page | 363 |
| container_title | Journal of voice |
| container_volume | 31 |
| creator | Bradley, Joseph P Barrow, Emily M Hapner, Edie R Klein, Adam M Johns, Michael M |
| description | Summary Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) ( P |
| doi_str_mv | 10.1016/j.jvoice.2016.09.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1839115230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0892199716301618</els_id><sourcerecordid>2042650866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-fb43ab34fc2ada2092007eea45b95460179d48ddd723fd83391fa1a0777961d63</originalsourceid><addsrcrecordid>eNqFUk1v1DAQjRCILoV_gJCPXJKO7SSOL0hLy0elSj3scuBkee0JOCT2Yier7r_Hqy0cuPQ0Hvm9N5r3pijeUqgo0PZqqIZDcAYrlrsKZAWMPStWtBO8rJuue16soJOspFKKi-JVSgMAsPz7srhgouNSdmJV9B_DvIzOLxPZhgfnyzW5Ccn5H2Qb0dtE-hDJ2trFzPmx2es0BesMuTmm_c_gnSZ6JppsMmNEcuvT7OZldsGT-wNGQoF8Rx3T6-JFr8eEbx7rZfHt86ft9dfy7v7L7fX6rjQNbeey39Vc73jdG6atZiAZgEDUdbOTTd0CFdLWnbVWMN7bjnNJe001CCFkS23LL4v3Z919DL8XTLOaXDI4jtpjWJJiULO2ga59GkqzRZQ2jEOG1meoiSGliL3aRzfpeFQU1CkMNahzGOoUhgKpchiZ9u5xwrKb0P4j_XU_Az6cAZgtOTiMKhmH3qB1Ec2sbHBPTfhfwOQsndHjLzxiGsISfbZbUZWYArU5HcTpHmjLs0re8A9m27C0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1839115230</pqid></control><display><type>article</type><title>Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bradley, Joseph P ; Barrow, Emily M ; Hapner, Edie R ; Klein, Adam M ; Johns, Michael M</creator><creatorcontrib>Bradley, Joseph P ; Barrow, Emily M ; Hapner, Edie R ; Klein, Adam M ; Johns, Michael M</creatorcontrib><description>Summary Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) ( P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.</description><identifier>ISSN: 0892-1997</identifier><identifier>EISSN: 1873-4588</identifier><identifier>DOI: 10.1016/j.jvoice.2016.09.022</identifier><identifier>PMID: 27839987</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acetylcholine Release Inhibitors - administration & dosage ; Acetylcholine Release Inhibitors - adverse effects ; Adductor spasmodic dysphonia ; Botox ; Botulinum toxin-A ; Botulinum Toxins, Type A - administration & dosage ; Botulinum Toxins, Type A - adverse effects ; Dosing ; Dysphonia - diagnostic imaging ; Dysphonia - drug therapy ; Dysphonia - physiopathology ; Female ; Georgia ; Humans ; Injections, Intramuscular ; Laryngeal dystonia ; Laryngeal Muscles - diagnostic imaging ; Laryngeal Muscles - drug effects ; Laryngeal Muscles - physiopathology ; Male ; Middle Aged ; Otolaryngology ; Recovery of Function ; Retrospective Studies ; Stroboscopy ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of voice, 2017-05, Vol.31 (3), p.363-365</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-fb43ab34fc2ada2092007eea45b95460179d48ddd723fd83391fa1a0777961d63</citedby><cites>FETCH-LOGICAL-c516t-fb43ab34fc2ada2092007eea45b95460179d48ddd723fd83391fa1a0777961d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0892199716301618$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27839987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bradley, Joseph P</creatorcontrib><creatorcontrib>Barrow, Emily M</creatorcontrib><creatorcontrib>Hapner, Edie R</creatorcontrib><creatorcontrib>Klein, Adam M</creatorcontrib><creatorcontrib>Johns, Michael M</creatorcontrib><title>Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years</title><title>Journal of voice</title><addtitle>J Voice</addtitle><description>Summary Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) ( P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.</description><subject>Acetylcholine Release Inhibitors - administration & dosage</subject><subject>Acetylcholine Release Inhibitors - adverse effects</subject><subject>Adductor spasmodic dysphonia</subject><subject>Botox</subject><subject>Botulinum toxin-A</subject><subject>Botulinum Toxins, Type A - administration & dosage</subject><subject>Botulinum Toxins, Type A - adverse effects</subject><subject>Dosing</subject><subject>Dysphonia - diagnostic imaging</subject><subject>Dysphonia - drug therapy</subject><subject>Dysphonia - physiopathology</subject><subject>Female</subject><subject>Georgia</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Laryngeal dystonia</subject><subject>Laryngeal Muscles - diagnostic imaging</subject><subject>Laryngeal Muscles - drug effects</subject><subject>Laryngeal Muscles - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Otolaryngology</subject><subject>Recovery of Function</subject><subject>Retrospective Studies</subject><subject>Stroboscopy</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0892-1997</issn><issn>1873-4588</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAQjRCILoV_gJCPXJKO7SSOL0hLy0elSj3scuBkee0JOCT2Yier7r_Hqy0cuPQ0Hvm9N5r3pijeUqgo0PZqqIZDcAYrlrsKZAWMPStWtBO8rJuue16soJOspFKKi-JVSgMAsPz7srhgouNSdmJV9B_DvIzOLxPZhgfnyzW5Ccn5H2Qb0dtE-hDJ2trFzPmx2es0BesMuTmm_c_gnSZ6JppsMmNEcuvT7OZldsGT-wNGQoF8Rx3T6-JFr8eEbx7rZfHt86ft9dfy7v7L7fX6rjQNbeey39Vc73jdG6atZiAZgEDUdbOTTd0CFdLWnbVWMN7bjnNJe001CCFkS23LL4v3Z919DL8XTLOaXDI4jtpjWJJiULO2ga59GkqzRZQ2jEOG1meoiSGliL3aRzfpeFQU1CkMNahzGOoUhgKpchiZ9u5xwrKb0P4j_XU_Az6cAZgtOTiMKhmH3qB1Ec2sbHBPTfhfwOQsndHjLzxiGsISfbZbUZWYArU5HcTpHmjLs0re8A9m27C0</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Bradley, Joseph P</creator><creator>Barrow, Emily M</creator><creator>Hapner, Edie R</creator><creator>Klein, Adam M</creator><creator>Johns, Michael M</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years</title><author>Bradley, Joseph P ; Barrow, Emily M ; Hapner, Edie R ; Klein, Adam M ; Johns, Michael M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-fb43ab34fc2ada2092007eea45b95460179d48ddd723fd83391fa1a0777961d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acetylcholine Release Inhibitors - administration & dosage</topic><topic>Acetylcholine Release Inhibitors - adverse effects</topic><topic>Adductor spasmodic dysphonia</topic><topic>Botox</topic><topic>Botulinum toxin-A</topic><topic>Botulinum Toxins, Type A - administration & dosage</topic><topic>Botulinum Toxins, Type A - adverse effects</topic><topic>Dosing</topic><topic>Dysphonia - diagnostic imaging</topic><topic>Dysphonia - drug therapy</topic><topic>Dysphonia - physiopathology</topic><topic>Female</topic><topic>Georgia</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Laryngeal dystonia</topic><topic>Laryngeal Muscles - diagnostic imaging</topic><topic>Laryngeal Muscles - drug effects</topic><topic>Laryngeal Muscles - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Otolaryngology</topic><topic>Recovery of Function</topic><topic>Retrospective Studies</topic><topic>Stroboscopy</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bradley, Joseph P</creatorcontrib><creatorcontrib>Barrow, Emily M</creatorcontrib><creatorcontrib>Hapner, Edie R</creatorcontrib><creatorcontrib>Klein, Adam M</creatorcontrib><creatorcontrib>Johns, Michael M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of voice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bradley, Joseph P</au><au>Barrow, Emily M</au><au>Hapner, Edie R</au><au>Klein, Adam M</au><au>Johns, Michael M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years</atitle><jtitle>Journal of voice</jtitle><addtitle>J Voice</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>31</volume><issue>3</issue><spage>363</spage><epage>365</epage><pages>363-365</pages><issn>0892-1997</issn><eissn>1873-4588</eissn><abstract>Summary Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) ( P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27839987</pmid><doi>10.1016/j.jvoice.2016.09.022</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0892-1997 |
| ispartof | Journal of voice, 2017-05, Vol.31 (3), p.363-365 |
| issn | 0892-1997 1873-4588 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1839115230 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acetylcholine Release Inhibitors - administration & dosage Acetylcholine Release Inhibitors - adverse effects Adductor spasmodic dysphonia Botox Botulinum toxin-A Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - adverse effects Dosing Dysphonia - diagnostic imaging Dysphonia - drug therapy Dysphonia - physiopathology Female Georgia Humans Injections, Intramuscular Laryngeal dystonia Laryngeal Muscles - diagnostic imaging Laryngeal Muscles - drug effects Laryngeal Muscles - physiopathology Male Middle Aged Otolaryngology Recovery of Function Retrospective Studies Stroboscopy Time Factors Treatment Outcome |
| title | Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A35%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botulinum%20Toxin-A%20Dosing%20Trends%20for%20Adductor%20Spasmodic%20Dysphonia%20at%20a%20Single%20Institution%20Over%2010%20Years&rft.jtitle=Journal%20of%20voice&rft.au=Bradley,%20Joseph%20P&rft.date=2017-05-01&rft.volume=31&rft.issue=3&rft.spage=363&rft.epage=365&rft.pages=363-365&rft.issn=0892-1997&rft.eissn=1873-4588&rft_id=info:doi/10.1016/j.jvoice.2016.09.022&rft_dat=%3Cproquest_cross%3E2042650866%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1839115230&rft_id=info:pmid/27839987&rft_els_id=S0892199716301618&rfr_iscdi=true |